1. Campbell RJ, Bronskill SE, Bell CM, Paterson JM, Whitehead M, Gill SS. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: A population–based analysis. Arch Ophthalmol. 2010; 128(3): 359-362. doi: 10.1001/archophthalmol.2010.19
2. Keenan TD, Wotton CJ, Goldacre MJ. Trends over time and geographical variation in rates of intravitreal injections in England. Br J Ophthalmol. 2012; 96(3): 413-418. doi: 10.1136/bjophthalmol-2011-300338
3. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreal injections. Retina. 2004; 24(5 Suppl): S3-S19. doi: 10.1097/00006982-200410001-00002
4. Genentech Inc. Lucentis 10mg/ml solution for injection. highlights of prescribing information. San Francisco, CA, USA. Web site. https://www.medicines.org.uk/emc/product/307/smpc. Accessed September 22, 2016.
5. Sigford DK, Reddy S, Moolineaux C, Schaal S. Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: A literature review and analysis. Clin Ophthalmol. 2015; 9: 773-781. doi: 10.2147/OPTH.S77067
6. DossarpsD, Bron AM, Koehrer P, Aho-Glele LS, Creuzot-Garcher C, FRCR net. Endophthalmitis after intravitreal injections: incidence, presentation, management and visual outcome. Am J Ophthalmol. 2015; 160(1): 17-25e1. doi: 10.1016/j.ajo.2015.04.013
7. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies. Retina. 2011; 31(4): 654-661. doi: 10.1097/IAE.0b013e31820a67e4
8. Mosfeghi AA, Rosenfeld PJ, Flynn JW Jr, et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: A six year experience at a university referral center. Retina. 2011; 31(4): 662-668. doi: 10.1097/IAE.0b013e31821067c4
9. Bhavsar AR, Googe JM, Stockdale CR, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: The diabetic retinopathy clinical research network laser-ranbizumab-triamcinolone clinical trials. Arch Ophthalmol. 2009; 127(12): 1581-1583. doi: 10.1001/archophthalmol.2009.304
10. Mason JO 3rd, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008; 28(4): 564-567. doi: 10.1097/IAE.0b013e3181633fee
11. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmtiis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008; 145(5): 879-882. doi: 10.1016/j.ajo.2007.12.036
12. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008; 28(10): 1395-1399. doi: 10.1097/IAE.0b013e3181884fd2
13. Hunyor AP, Merani R, Darbar A, Korobelnik JF, Lanzetta P, Okada AA. Topical antibiotics and intravitreal injections. Acta Ophthalmol. 2018; 96(5): 435-441. doi: 10.1111/aos.13417
14. Halachmi–Eyal O, Lang Y, Keness Y, Miron D. Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone iodine 5% alone to reduce bacterial colonization in the conjunctival sac. J Cataract Refract Surg. 2009; 35(12): 2109-2114. doi: 10.1016/j.jcrs.2009.06.038
15. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology. 2009; 116(8): 1498-1501. doi: 10.1016/j.ophtha.2009.02.024
16. Benoistd’Azy C, Pereira B, Naughton G, Chiambaretta F, Dutheil F. Antibioprophylaxis in prevention of endophthalmitis in intravitreal injection: A systematic review and meta-analysis. PLoS One. 2016; 11(6): e0156431. doi: 10.1371/journal.pone.0156431
17. Bhavsar AR, Stockdale CR, Ferris FL 3rd, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol. 2012; 130(6): 809-810. doi: 10.1001/archophthalmol.2012.227
18. Bhatt SS, Stephen KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: Effect on endophthalmitis rate. Retina. 2011; 31(10): 2032-2036. doi: 10.1097/IAE.0b013e31820f4b4f
19. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endopthalmitis and use of antibiotic prohylaxis after intravitreal injections. Ophthalmology. 2012; 119(8): 1609-1614. doi: 10.1016/j.ophtha.2012.02.014
20. Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitrealbevacizumab injection in a single clinical center. Retina. 2013; 33(5): 971-974. doi: 10.1097/IAE.0b013e31826f0675
21. Storey P, Dollin M, Pitcher J, et al. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014; 121(1): 283-289. doi: 10.1016/j.ophtha.2013.08.037
22. Bhavsar AR, Sandler DR. Eliminating antibiotic prophylaxis for intravitreal injections: A consecutive series of 18839 injections by a single surgeon. Retina. 2015; 35(4): 783-788. doi: 10.1097/IAE.0000000000000392
23. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitidunal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol. 2011; 129(9): 1180-1188. doi: 10.1001/archophthalmol.2011.213
24. Meredith TA, McCannel CA, Barr C, et al. Postinjectionendophthalmitis in the comparison of age-related macular degeneration treatment trials (CATT). Ophthalmology. 2015; 122(4): 817-821. doi: 10.1016/j.ophtha.2014.10.027
25. Gupta A, Sun JK, Silva PS. Complications of intraviterous injections in patients with diabetes. 2018; 33(1): 42-50. doi: 10.1080/08820538.2017.1353811
26. Stem MS, Todorich B, Yonekawa Y, Capone A Jr, Williams GA, Ruby AJ. Incidence and Visual Outcomes of Culture-Proven Endophthalmitis Following Dexamethasone Intravitreal Implant. JAMA 2017; 135(4): 379-382. doi: 10.1001/jamaophthalmol.2016.5883
27. Menchini F, Toneatto G, Miele A, Donati S, Lanzetta P, Virgili G. Antibiotic prophylaxis for preventing endophthlamitis after intravitreal injection: A systematic review. Eye (Lond). 2018; 32(9): 1423-1431. doi: 10.1038/s41433-018-0138-8
28. Li AL, Wykoff CC, Wang R, et al. Endophthalmitis after intravitreal injection: Role of prophylactic topical ophthalmic antibiotics. Retina. 2016; 36(7): 1349-1356. doi: 10.1097/IAE.0000000000000901
29. St Leger AJ, Desai VJ, Drummond RA, et al. An ocular commensal protects against corneal infection by driving an interleukin-17 response from mucosal γδ T cells. Immunity. 2017; 47(1): 148-158. doi: 10.1016/j.immuni.2017.06.014
30. Dave SB, Toma HS, Kim SJ. Changes in ocular flora in eyes exposed to ophthalmic antibiotics. Ophthalmology. 2013; 120(5): 937-941. doi: 10.1016/j.ophtha.2012.11.005
31. Kim SJ, Toma HS, Midha NK, Cherney EF, Recchia FM, Doherty TJ. Antibiotic resistance of conjunctiva and nasopharynx evaluation study: A prospective study of patients undergoing intravitreal injections. Ophthalmology. 2010; 117(12): 2372-2378. doi: 10.1016/j.ophtha.2010.03.034
32. Trimawithana TR, Young S, Bunt CR, Green C, Alany RG. Drug delivery to the posterior segment of the eye. Drug Discov Today. 2011; 16(5-6): 270-277. doi: 10.1016/j.drudis.2010.12.004
33. Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina. 2006; 26(2): 191-195. doi: 10.1097/00006982-200602000-00012
34. Hsu J. Minimizing the risk of endophthalmitis after injection. Ophthalmol Retina. 2019; 3(1): 1-2. doi: 10.1016/j.oret.2018.10.011
35. Hsu J, Gerstenblith AT, Garg SJ, Vander JF. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics. Am J Ophtalmol. 2014; 157(3): 514-518. doi: 10.1016/j.ajo.2013.10.003
36. Lanker Klossner B, Widmer HR, Frey F. Nondevelopment of resistance by bacteria during hospital use of povidone-iodine. Dermatology. 1997; 195(Suppl 2): 10-13. doi: 10.1159/000246024
37. Friedman DA, Mason III JO, Emond T, MsGwinJr G. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina. 2013; 33(5): 975-981. doi: 10.1097/IAE.0b013e3182877585
38. Levinson JD, Garfunkel RA, Berinstein DM, et al. Timing of povidone iodine application to reduce the risk of endophthalmitis after intravitreal injections. Ophthalmol Retina. 2018; 2(7): 654-658. doi: 10.1016/j.oret.2017.06.004
39. Koemer JC, George MJ, Meyer DR, et al. Povidone-iodine concentration and dosing in cataract surgery. Surv Ophthalmol. 2018; 63(6): 862-868. doi: 10.1016/j.survophthal.2018.05.002
40. Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014; 34 Suppl 12: S1-S18. doi: 10.1097/IAE.0000000000000399
41. Diabetic Retinopathy Clinical Research Network. Scott IU, Edwards Ar, et al. A phase II randomized, clinical trial of intravitreal for diabetic macular edema. Ophthalmology. 2007; 114(10): 1860-1867. doi: 10.1016/j.ophtha.2007.05.062
42. Royal College of Ophthalmologists. Age-related macular degeneration: Gıidelines for management. Web site. http://www.rcophth.ac.uk/wp-content/uploads/2014/12/2013-SCI-318-RCOphth-AMD-Guidelines-Sept-2013-FINAL-2.pdf. Accessed September 22, 2016.
43. American Academy of Ophthalmology. How to give intravitreal injections. Web site. https://www.aao.org/eyenet/article/how-to-give-intravitreal-injections. Accessed September 22, 2016.
44. American Academy of Ophthalmology. Five things physicians and patients should question. Web site. http://www.choosingwisely. Org/societies/american-academy-of-ophthalmology/. Released February 21, 2013. Accessed September 22, 2016.
45. Meyer CH, Mennel S, Eter N. Endophthalmitis rate mit und ohnetopische post-operative antibiotikgabe nach intravitrealer Avastin-Injektion. Der Ophthalmologe. 2007; 104(11): 952-957. doi: 10.1007/s00347-007-1634-6
46. Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: A retrospective multicenter study. Retina. 2014; 34(1): 12-17. doi: 10.1097/IAE.0b013e31829f74b0
47. Ramel JC, Bron AM, Isaico R, Meillon C, Binquet C, Creuzot-Garcher C. Incidence of endophthalmitis after intravitreal injection: is antibiotic prophylaxis mandatory? J Fr Ophthalmol. 2014; 37(4): 273-279. doi: 10.1016/j.jfo.2014.01.003
48. Stranak Z, Veith M, Studeny P, Pencak M. The incidence of endophtalmitis after the application of intravitreal injections in FNKV with regard to various prophylactic antibiotic regimens [In: Czech]. Ceska Slov Oftalmol. 2014; 70(5): 184-188.
49. FalavarjaniKG, Aghamirsalim M, Modarres M, et al. Endophthalmitis after resident-performed intravitreal bevacizumab injection. Can J Ophthalmol. 2015; 50(1): 33-36. doi: 10.1016/j.jcjo.2014.09.005
50. Pachuo MA, Sahto AA, Quraishi MH, Abbasi AM. Role of post-injection antibiotics after intravitrealbevacizumab injection in preventing endophthalmitis. Pak J Ophthalmol. 2015; 31: 41-47.
51. Bhavsar AR, Glassman AR, Stockdale CR, Jampol LM, Diabetic Retinopathy Clinical Research Network. Elimination of topical antibiotics for intravitreous injections and the importance of using povidone-iodine: Update from the DRCR.net. JAMA Ophthalmol. 2016; 134(10): 1181-1183. doi: 10.1001/jamaophthalmol.2016.2741